Table 1.
Characteristics of patients with nonmuscle-invasive TCC of the bladder.
| Patient number | 1, 2 | 3 | 4 | 5 | 6 | 7 |
|---|---|---|---|---|---|---|
| Age at transplant | 66 | 77 | 82 | 66 | 63 | 45 |
| Type of transplant | Liver | Renal | Renal | Renal | Liver | Renal |
| Age at diagnosis | 66 | 79 | 83 | 72 | 65 | 47 |
| Immunosuppression | FK, MMF, Pred | FK, Pred | FK | FK, MMF | FK, Pred | FK, Pred |
| Clinical stage | T1NxMx | T1NxMx | TisNxMx | TisNxMx | TisNxMx | T1N0Mx |
| Histology | TCC | TCC | CIS | CIS | CIS | TCC |
| Grade | Low | Low | High | High | High | High |
| Treatment | TURBT | TURBT | TURBT | TURBT | TURBT | Cystectomy, ureteroureterostomy |
| Adjuvant therapy | None | BCG | BCG | BCG | BCG | Mitomycin C |
| Followup (months) | 28, 24 | 40 | 36 | 84 | 42 | 98 |
| Recurrence | None | Local | Local | None | Local | None |
FK: tacrolimus; MMF: mycophenolate mofetil; Pred: prednisone; CIS: carcinoma in site; TURBT: transurethral resection bladder tumor; BCG: bacille-Calmette Guerin.